866-997-4948(US-Canada Toll Free)

Kennedy s Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 35 Pages

Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kennedys Disease (Spinal and Bulbar Muscular Atrophy) Pipeline Review, H2 2016, provides an overview of the Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline landscape.

Spinal and bulbar muscular atrophy or Kennedy disease is a disorder of specialized nerve cells that control muscle movement. These nerve cells originate in the spinal cord and the part of the brain that is connected to the spinal cord Symptoms include tremors, speech difficulties, muscle weakness, muscle wastage, muscle cramps and spasms and gynaecomastia. Treatment includes balanced diet and medications to reduce muscle cramps and tremors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kennedys Disease (Spinal and Bulbar Muscular Atrophy) Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Kennedys Disease (Spinal and Bulbar Muscular Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively.

Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kennedys Disease (Spinal and Bulbar Muscular Atrophy) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) Overview 6
Therapeutics Development 7
Pipeline Products for Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Overview 7
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics under Development by Companies 8
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Products under Development by Companies 11
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Companies Involved in Therapeutics Development 12
AndroScience Corp 12
Armgo Pharma Inc 13
Novartis AG 14
Vybion Inc 15
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ARM-210 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ASC-J9/ASC-JM.X1 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ASCJ-9 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
BVS-857 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
INT-41 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Rycal - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Dormant Projects 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables
Number of Products under Development for Kennedys Disease (Spinal and Bulbar Muscular Atrophy), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by AndroScience Corp, H2 2016 12
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Armgo Pharma Inc, H2 2016 13
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Novartis AG, H2 2016 14
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Pipeline by Vybion Inc, H2 2016 15
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Stage and Target, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 20
Number of Products by Stage and Route of Administration, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 24
Kennedys Disease (Spinal and Bulbar Muscular Atrophy) - Dormant Projects, H2 2016 33

List of Figures
Number of Products under Development for Kennedys Disease (Spinal and Bulbar Muscular Atrophy), H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 10
Assessment by Monotherapy Products, H2 2016 16
Number of Products by Targets, H2 2016 17
Number of Products by Stage and Targets, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 19
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Routes of Administration, H2 2016 21
Number of Products by Stage and Routes of Administration, H2 2016 21
Number of Products by Molecule Types, H2 2016 23
Number of Products by Stage and Molecule Types, H2 2016 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *